Erratum: Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis (Journal of Clinical Oncology DOI: 10.1200/JCO.2015.61.3778);Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis

Journal of Clinical Oncology

Volumn 34, Issue 3, 2016, Pages 219-226

  Tao, Randa ^a   Krishnan, Sunil ^a   Bhosale, Priya R ^a   Javle, Milind M ^a   Aloia, Thomas A ^a   Shroff, Rachna T ^a   Kaseb, Ahmed O ^a   Bishop, Andrew J ^a   Swanick, Cameron W ^a   Koay, Eugene J ^a   Thames, Howard D ^a   Hong, Theodore S ^b   Das, Prajnan ^a   Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY STENOSIS; BILIARY TRACT DISEASE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; RETROSPECTIVE STUDY; STOMACH HEMORRHAGE; VERY ELDERLY; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CONFORMAL RADIOTHERAPY; MIDDLE AGED; RADIATION RESPONSE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84955446072     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.19.00518     Document Type: Erratum

References (19)

1. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353-1357, 2001
2. Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10, 2002
3. Shaib YH, Davila JA, McGlynn K, et al: Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol 40:472-477, 2004
4. Vauthey JN, Blumgart LH: Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 14:109-114, 1994
5. Chou FF, Sheen-Chen SM, Chen YS, et al: Surgical treatment of cholangiocarcinoma. Hepatogastroenterology 44:760-765, 1997
6. Shinohara ET, Mitra N, Guo M, et al: Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 72:1495-1501, 2008
7. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281, 2010
8. Dawson LA, McGinn CJ, Normolle D, et al: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18:2210-2218, 2000
9. Zeng ZC, Tang ZY, Fan J, et al: Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: A retrospective analysis of 75 patients. Cancer J 12:113-122, 2006
10. Crane CH, Macdonald KO, Vauthey JN, et al: Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 53:969-974, 2002
11. Shiu AS, Chang EL, Ye JS, et al: Near simultaneous computed tomography image-guided stereotactic spinal radiotherapy: An emerging paradigm for achieving true stereotaxy. Int J Radiat Oncol Biol Phys 57:605-613, 2003
12. Wong JW, Sharpe MB, Jaffray DA, et al: The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 44:911-919, 1999
13. Peng Y, Vedam S, Chang JY, et al: Implementation of feedback-guided voluntary breath-hold gating for cone beam CT-based stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 80:909-917, 2011
14. Weber SM, Jarnagin WR, Klimstra D, et al: Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384-391, 2001
15. Sulpice L, Rayar M, Boucher E, et al: Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg 99:1711-1717, 2012
16. Ohtsuka M, Ito H, Kimura F, et al: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencingsurvival. Br J Surg 89:1525-1531, 2002
17. Ben-Josef E, Normolle D, Ensminger WD, et al: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 23:8739-8747, 2005
18. Tse RV, Hawkins M, Lockwood G, et al: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:657-664, 2008
19. Chen YX, Zeng ZC, Tang ZY, et al: Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: A retrospective analysis of 84 patients. BMC Cancer 10:492, 2010